Cellectis | LinkedIn (original) (raw)
``
Recherche en biotechnologie
Cellectis is developing life-changing product candidates to target and eradicate cancer cells.
À propos
Cellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 24 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its proprietary gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to target and eradicate cancer cells. As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing life-saving UCART product candidates to address unmet needs for multiple cancers including B-cell acute lymphoblastic leukemia (B-ALL), non-Hodgkin lymphoma (NHL) and acute myeloid leukemia (AML). Cellectis headquarters are in Paris, France, with additional locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com. To learn more about our community guidelines, visit: http://www.cellectis.com/en/social-media-guidelines/ Follow our other social media accounts: @cellectis on Twitter and Cellectis YouTube TALEN® is a registered trademark owned by the Cellectis Group.
Secteur
Recherche en biotechnologie
Taille de l’entreprise
51-200 employés
Siège social
Paris
Type
Société cotée en bourse
Fondée en
1999
Domaines
Gene editing, Life sciences, Oncology, T-Cell therapies, genome engineering, allogeneic et off-the-shef CART therapies
Lieux
Employés chez Cellectis
Nouvelles
- Here is what happen when you co-culture T-cells and cancer cells: Just as an ant farm allows us to observe ant behavior in a controlled environment, co-culturing T-cells and cancer cells creates a miniature "immune system vs. tumor" battleground in the lab. In this video: Blue shows the position of target cells Red the position of T cells and Yellow when there are T-cell interaction Confined Space: Like ants in their farm, cells interact within a defined area. Observable Interactions: We can watch T-cells "hunt" cancer cells in real-time. Controlled Environment: Researchers manipulate conditions to study different scenarios. Complex Behaviors: Both systems reveal intricate social dynamics and survival strategies. Why It Matters: This "cellular ant farm" helps us understand how our immune system fights cancer and how tumors evade attack. It's a crucial tool for developing more effective immunotherapies. Thanks to Nanolive SA for the great video!
- Cellectis a republié ceci
President, AstraZeneca France
5 j.
En novembre 2023, nous avions annoncé un partenariat stratégique entre AstraZeneca et Cellectis, biotech française spécialisée dans l’édition du génome, afin de développer la prochaine génération de produits de thérapie cellulaire et génique en oncologie, en immunologie et dans les maladies rares. Pour célébrer la première année de cette collaboration, nous avons invité André Choulika, directeur général de Cellectis, dans nos locaux pour répondre aux questions de nos collaborateurs. Devant l’enthousiasme des équipes, nous avons souhaité en tirer non pas une, mais deux vidéos, tant le contenu qu’il a partagé est riche et enthousiasmant. Je vous propose aujourd'hui de découvrir la première vidéo, qui dresse un état des lieux de ce partenariat, ainsi que les motivations et les ambitions de notre alliance. Rendez-vous prochainement pour la seconde vidéo ! Un grand merci à André pour sa présence et ses propos porteurs d’espoir pour de nombreux patients. - Sickle cell disease (SCD) affects 5 million people worldwide, making it one of the most common inherited blood disorders. Recent breakthroughs in gene therapy have ushered in a new era of hope for SCD patients, offering a potential cure by addressing the genetic root of the disease. Here is Cellectis’ approach to treat the disease, using TALEN® gene editing tool. As we move forward, it's essential to continue educating ourselves and others about the potential groundbreaking treatments. By bridging the knowledge gap, we can ensure that patients and healthcare providers make informed decisions about the future of SCD treatment. To learn more about the research, follow this link: https://lnkd.in/e68HPhaS
- Natural killer (NK) cells are game changers in cancer treatment. Why? ✅ NK cells can recognize and kill tumor cells without prior priming and can be adoptively transferred in allogenic settings to treat multiple cancers without causing graft-versus-host disease. But: ❌ Sourcing and producing large quantity of therapeutic NK cells is difficult due to their poor intrinsic expansion capabilities. ❌ Their clinical efficacy is often compromised by tumor-intrinsic immunosuppressive microenvironments. Additionally: 💡 Induced pluripotent stem cells (iPSC) could represent a relevant cellular scaffold to overcome these main two challenges. Indeed, iPSC are easy to source, bears unlimited self-renewal capability and high propensity for genomic modification by gene editing technics. 💡 These unique features could enable generating an iPSC-derived NK cell endowed with additional functions that promote optimal expansion of iPSC-derived NK cells (iNK) and unleash their full anticancer activity, even in tumor-intrinsic immunosuppressive microenvironments. Knowing this, Cellectis and Cytovia Therapeutics developed a new approach: A TALEN-edited iPSC-derived NK cells (iNK-cells) containing an IL-15 knocked-in at the B2M locus and the TGFbR2 knockout (KO). This strategy promotes IL-15 expression in iNKs, PBNKs, and CBNKs while minimizing it in human iPSCs. Furthermore, engineered iNK cells show antitumor activity, better survival in autonomous growth and are resistant to the suppressive TGF-β signaling. Why it’s interesting? ✅ These features prevent the constitutive expression of exogenous IL-15 in human iPSCs, potentially mitigating the negative effects of such cytokine on the physiological behavior and pluripotency of iPSCs. ✅ It also improves immune functions of iNK-cells by overcoming the immunosuppressive tumor microenvironment (TME). This strategy can apply to other iPSC-derived cell therapies, such as iPSC-derived T-cell therapies. It offers an opportunity to generate unlimited, homogeneous, and standardized cells for off-the-shelf therapies compatible with adoptive transfer in allogenic settings. You want to know more? Here is the link to the research published in Cell Reports by Cell Press:https://lnkd.in/e3vjGZqiVisual credits: NIH Image Gallery from Bethesda, Maryland, USA
- We are stronger together. This is the tagline of Odysséa Organisation, a race organized every year to support breast cancer research. On October 6, Cellectis employees in Paris decided to join the 45,000 participants running in the rain to support scientific research. We at Cellectis remain committed to finding a cure for cancer patients and strive every day to make an impact that brings us closer to a future without this disease. Thanks to all the participants, 1 million euros were collected, and 347 km were covered for breast cancer research. Let’s aim to do even more next year! ✊ #ensembleonestencoreplusfort